TABLE OF CONTENTS
1 INTRODUCTION 10
1.1 OBJECTIVES OF THE STUDY 10
1.2 MARKET DEFINITION 10
1.3 OVERVIEW OF U.S. PSYCHEDELIC DRUGS MARKET 10
1.4 LIMITATION 11
1.5 MARKETS COVERED 12
2 MARKET SEGMENTATION 13
2.1 GEOGRAPHICAL SCOPE 14
2.2 YEARS CONSIDERED FOR THE STUDY 14
2.3 CURRENCY AND PRICING 14
2.4 DBMR TRIPOD DATA VALIDATION MODEL 15
2.5 MULTIVARIATE MODELLING 18
2.6 PRODUCTS LIFELINE CURVE 18
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 19
2.8 VENDOR SHARE ANALYSIS 20
2.9 SECONDARY SOURCES 21
2.10 ASSUMPTIONS 21
3 EXECUTIVE SUMMARY 22
4 PREMIUM INSIGHTS 25
4.1 PRACTICING PSYCHIATRISTS 26
4.2 PIPELINE PRODUCTS 26
5 EPIDEMIOLOGY 30
6 MARKET OVERVIEW 31
6.1 DRIVERS 33
6.1.1 GROWING ACCEPTANCE OF PSYCHEDELIC DRUGS FOR TREATING DEPRESSION 33
6.1.2 INCREASING PREVALENCE OF DEPRESSION AND MENTAL DISORDERS 34
6.1.3 RISING AWARENESS TOWARDS MENTAL HEALTH 41
6.2 RESTRAINTS 42
6.2.1 STRINGENT REGULATIONS FOR PSYCHEDELIC DRUGS 42
6.2.2 HIGH COST OF PSYCHEDELIC DRUG 44
6.3 OPPORTUNITIES 46
6.3.1 INCREASING R&D ACTIVITIES IN PSYCHEDELIC DRUGS 46
6.3.2 BREAKTHROUGH THERAPY DESIGNATION BY REGULATORY AUTHORITY 47
6.4 CHALLENGE 50
6.4.1 SIDE EFFECTS ASSOCIATED WITH PSYCHEDELIC DRUGS 50
7 U.S. PSYCHEDELIC DRUGS MARKET, BY SOURCE 52
7.1 OVERVIEW 53
7.2 SYNTHETIC 55
7.3 NATURAL 55
8 U.S. PSYCHEDELIC DRUGS MARKET, BY TYPE 56
8.1 OVERVIEW 57
8.2 DISSOCIATIVE 59
8.3 EMPATHOGENS 59
8.4 SEROTONERGIC (CLASSICAL PSYCHEDELIC DRUGS) 59
9 U.S. PSYCHEDELIC DRUGS MARKET, BY APPLICATION 60
9.1 OVERVIEW 61
9.2 NARCOLEPSY 63
9.3 TREATMENT- RESISTANT DEPRESSION (TRD) 63
9.4 POST-TRAUMATIC STRESS DISORDER (PTSD) 63
9.5 MAJOR DEPRESSIVE DISORDER 64
9.6 OTHERS 64
10 U.S. PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION 66
10.1 OVERVIEW 67
10.2 ORAL 69
10.3 INTRANASAL 69
10.4 PARENTERAL 69
10.5 OTHERS 69
11 U.S. PSYCHEDELIC DRUGS MARKET, BY DRUGS 71
11.1 OVERVIEW 72
11.2 GAMMA-HYDROXYBUTYRIC ACID (GHB) 74
11.3 KETAMINE 74
11.4 3,4-METHYLENEDIOXYMETHAMPHETAMINE (ECSTASY) 74
11.5 PSILOCYBIN 75
12 U.S. PSYCHEDELIC DRUGS MARKET, BY END USER 76
12.1 OVERVIEW 77
12.2 HOSPITAL 79
12.3 SPECIALTY CLINICS 79
12.4 RESEARCH ORGANISATION 80
12.5 OTHERS 80
13 U.S. PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL 81
13.1 OVERVIEW 82
13.2 HOSPITAL PHARMACY 84
13.3 COMPOUNDING PHARMACY 84
13.4 OTHERS 84
14 U.S. PSYCHEDELIC DRUGS MARKET, COMPANY LANDSCAPE 85
15 COMPANY PROFILE 86
15.1 JAZZ PHARMACEUTICALS, INC. 86
15.1.1 COMPANY SNAPSHOT 86
15.1.2 REVENUE ANALYSIS 86
15.1.3 PRODUCT PORTFOLIO 87
15.1.4 PIPELINE PORTFOLIO 87
15.1.5 RECENT DEVELOPMENTS 87
15.2 JOHNSON & JOHNSON SERVICES, INC. 88
15.2.1 COMPANY SNAPSHOT 88
15.2.2 REVENUE ANALYSIS 88
15.2.3 PRODUCT PORTFOLIO 89
15.2.4 RECENT DEVELOPMENTS 89
16 POTENTIAL PLAYERS PROFILE 90
16.1 AVADEL PHARMACEUTICALS, PLC. 90
16.1.1 COMPANY SNAPSHOT 90
16.1.2 REVENUE ANALYSIS 90
16.1.3 PIPELINE PORTFOLIO 91
16.1.4 RECENT DEVELOPMENT 91
16.2 AMNEAL PHARMACEUTICALS LLC. 92
16.2.1 COMPANY SNAPSHOT 92
16.2.2 REVENUE ANALYSIS 92
16.2.3 PIPELINE PORTFOLIO 93
16.2.4 RECENT DEVELOPMENT 93
16.3 CELON PHARMA SA 94
16.3.1 COMPANY SNAPSHOT 94
16.3.2 PIPELINE PORTFOLIO 94
16.3.3 RECENT DEVELOPMENT 94
?
16.4 COMPASS 95
16.4.1 COMPANY SNAPSHOT 95
16.4.2 PIPELINE PORTFOLIO 95
16.4.3 RECENT DEVELOPMENTS 95
16.5 DEVELCO PHARMA SCHWEIZ AG 96
16.5.1 COMPANY SNAPSHOT 96
16.5.2 PIPELINE PORTFOLIO 96
16.5.3 RECENT DEVELOPMENT 96
16.6 DOUGHLAS PHARMACEUTICALS LIMITED 97
16.6.1 COMPANY SNAPSHOT 97
16.6.2 PRODUCT PORTFOLIO 97
16.6.3 RECENT DEVELOPMENT 97
16.7 HIKMA PHARMACEUTICALS PLC 98
16.7.1 COMPANY SNAPSHOT 98
16.7.2 REVENUE ANALYSIS 98
16.7.3 PRODUCT PORTFOLIO 99
16.7.4 RECENT DEVELOPMENTS 99
16.8 NEURORX, INC. 100
16.8.1 COMPANY SNAPSHOT 100
16.8.2 PRODUCT PORTFOLIO 100
16.8.3 RECENT DEVELOPMENTS 100
16.9 USONAINSTITUTE.ORG 101
16.9.1 INSTITUTE SNAPSHOT 101
16.9.2 PIPELINE PORTFOLIO 101
16.9.3 RECENT DEVELOPMENTS 101
17 QUESTIONNAIRE 102
18 RELATED REPORT 104
?